$OTLK
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Healthcare
Sector
Biotechnology
Industry
Robert Charles Jahr
CEO
23
Employees
$0.59
Current Price
$24.26M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 4 | 4 | $243,630.82 | 561,174 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 4 | 4 | $243,630.82 | 561,174 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 4 | 4 | $243,630.82 | 561,174 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 4 | 4 | $243,630.82 | 561,174 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 4 | 4 | $243,630.82 | 561,174 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 27, 2026 | Sukhtian Faisal Ghiath Director | Purchase | 122,174 | $0.41 | $50,005.82 | View Details |
| May 26, 2026 | Haddadin Yezan Munther Director | Purchase | 34,000 | $0.44 | $14,960.00 | View Details |
| May 26, 2026 | THURMAN RANDY H Director | Purchase | 5,000 | $0.43 | $2,145.00 | View Details |
| May 26, 2026 | HILZINGER KURT J Director | Purchase | 400,000 | $0.44 | $176,520.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.